R. Scott Shean

Mr. Shean's representative transactions include:

• Obagi in its US$1.2 billion business combination with Waldencast and Milk Makeup
• Zogenix in its US$2 billion sale to UCB ChemoCentryx in its US$3.7 billion sale to Amgen
• OmniAb in its US$850 million merger with Avista Public Acquisition Corp.
• Momenta Pharmaceuticals in its US$6.5 billion acquisition by J&J
• Ra Pharma in its US$2.5 billion acquisition by UCB
• Ligand Pharmaceuticals in its US$500 million acquisition of Pfenex
• Allergan (fka Actavis/ Watson) in its:
  • US$40.5 billion sale of its Global Generic Pharmaceuticals Business to Teva
  • US$25 billion acquisition of Forest Laboratories
  • £306 million acquisition of Auden Mckenzie Holdings Limited
  • US$8.5 billion acquisition of Warner Chilcott
  • Watson Pharmaceuticals in its US$5.65 billion acquisition of Actavis Group and related financings
  • Watson Pharmaceuticals in its US$1.8 billion acquisition of Arrow Group
  • Watson Pharmaceuticals in its US$2 billion acquisition of Andrx Corporation
• Ignyta, Inc. in its US$1.7 billion acquisition by Roche  
• Idera in its proposed merger with BioCryst
• Akebia in its merger with Keryx
• Sobi in its US$1.5 billion acquisition of RSV Products from AstraZeneca
• Vizio in its US$2 billion sale to LeEco
• 5.11 Tactical in its US$400 million sale to Compass Diversified Holdings
• Receptos in its US$7.2 billion acquisition by Celgene
• Questcor Pharmaceuticals in its US$5.6 billion sale to Mallinckrodt plc
• Ariosa Diagnostics in its acquisition by Roche
• Avanir Pharmaceuticals in its US$3.5 billion acquisition by Otsuka Pharmaceutical
• J.P. Morgan as financial advisor to Thermo Fisher in its US$13.6 billion acquisition of Life Technologies
• Medicis Pharmaceutical in the US$2.6 billion acquisition by Valeant Pharmaceuticals
• Perella Weinberg Partners, as financial advisor to One Lambda in the pending acquisition by Thermo Fisher Scientific for US$925 million
• Goldman, Sachs & Co. in the US$7 billion acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb
• Quest Software in its US$2.4 billion acquisition by Dell
• Complete Production Services in its US$6.2 billion merger with Superior Energy Services
• Clarient in its US$600 million sale to General Electric
• Visiogen, Inc. in its US$400 million sale to Abbott Laboratories
• HCP, Inc. in its US$3 billion acquisition of Slough Estates USA
• ICOS Corporation in its US$2.1 billion sale to Eli Lilly
• FileNet Corporation in its US$1.6 billion sale to IBM
• Varco International, Inc. in its US$5 billion merger with National Oilwell
• Harrah’s Entertainment, Inc. in its US$10.3 billion acquisition of Caesars Entertainment
• Pan Pacific Retail Properties, Inc. in its multi-billion dollar acquisitions of Western Properties Trust and Center Trust, Inc.
• Paul Frank Industries in its sale to Saban Capital
• Automotive.com in its sale to Primedia, Inc.